Ocular Therapeutix™ to Participate in March Investor Conferences

Core Insights - Ocular Therapeutix, Inc. is set to participate in multiple investor conferences in March 2026, showcasing its commitment to engaging with the investment community [1][2][3] Conference Participation - The company will present at the TD Cowen 46 Annual Health Care Conference on March 2, 2026, with a fireside chat led by Pravin U. Dugel, MD, from 9:10 to 9:40 AM ET in Boston, MA [2] - Ocular will also participate in the Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami, FL [2] - Another fireside chat is scheduled for the Citizens Life Sciences Conference on March 11, 2026, from 9:00 to 9:25 AM ET, again featuring Pravin U. Dugel, MD [2] - The Barclays 28 Annual Global Healthcare Conference will take place on March 11, 2026, in Miami, FL [3] - The RBC Capital Markets Ophthalmology Conference is set for March 24, 2026, with a virtual fireside chat from 9:30 to 10:00 AM ET, presented by Pravin U. Dugel, MD [3] Product Pipeline - Ocular Therapeutix is focused on redefining the retina experience with its investigational product AXPAXLI™ (OTX-TKI), currently in Phase 3 clinical trials for wet age-related macular degeneration and diabetic retinal disease [4] - The company’s commercial product DEXTENZA is an FDA-approved corticosteroid for treating ocular inflammation and pain post-surgery, as well as ocular itching associated with allergic conjunctivitis [5] - Ocular is also advancing its investigational product OTX-TIC, a travoprost intracameral hydrogel that has completed Phase 2 trials for open-angle glaucoma or ocular hypertension, with next steps currently under evaluation [5]